Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Neurologic Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Neurologic Other
    Vasopressin-Receptor Antagonists May Help Treat Wide Range of Conditions - (DGNews)
    Corticosteroids and mortality in children with bacterial meningitis - (JAMA)
    US Guidelines: Botulinum Toxin Effective in Many Neurological Disorders, Not Headache - (DGNews)
    Arachnoid Opening With Dural Graft May Provide Optimal Treatment for Patients With Chiari I Malformation With Syringomyelia: Presented at AANS - (DGDispatch)
    Long-term Follow-up Needed for Patients Treated Successfully for Cushing's Disease After Trans-Sphenoidal Surgery: Presented at AANS - (DGDispatch)

    News archive

     Recent webcasts/CME - Neurologic Other
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Modifiable Risk Factors Underlie Higher Dementia Rates in African Americans
    • Beliefs About Dementia Among Hispanics Impede Diagnosis and Treatment
    • Brain Cooling for the Treatment of Perinatal Hypoxic-Ischemic Encephalopathy
      Delirium Update

      Webcasts/CME archive

       Recent cases - Neurologic Other
        Bilateral Superficial Peroneal Nerve Entrapment Secondary to Anorexia Nervosa: A Case Report
        A Ganglion Cyst at the Elbow Causing Superficial Radial Nerve Compression: A Case Report
        Postangiographic Contrast Enhancement Mimicking Acute Subdural Hemorrhage in a Patient with Severe Occipital Headache and Neurological Symptoms: A Case Report
        Accidental Carbon Monoxide Poisoning Presenting Without a History of Exposure: A Case Report
        A Japanese Patient of Congenital Hypothyroidism with Cerebellar Atrophy

        Cases archive
          




        my personal edition > neurologic other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Deep-Brain Stimulation Shows Promise for Treatment of Refractory Obsessive-Compulsive Disorder: Presented at AANS

          By Mary Beth Nierengarten

          CHICAGO -- May 1, 2008 -- Patients suffering from obsessive-compulsive disorder (OCD) unresponsive to traditional medical and psychological therapies may benefit from surgical intervention with deep-brain stimulation (DBS), according to a study presented here at the 76th Annual Meeting of the American Association of Neurological Surgeons (AANS).

          Lead author Ali R. Rezai, MD, Jane & Lee Seidman Chair in Functional Neurosurgery, and Director, Center for Neurological Restoration, Cleveland Clinic, Cleveland, Ohio, reported here on April 28 on the first 26 patients treated with DBS at 4 centres between 1998 and 2003.

          All patients in the study were deemed to have severe OCD as measured by a Yale-Brown Obsessive-Compulsive Scale (YBOCS) score greater than 28 and had suffered from OCD for 8 to 14 years (mean of 22 +-1.5 years). All subjects had failed to achieve successful treatment with prior medication (at least 2 adequate drug regimens) and behavioural therapy (at least 20 sessions). The patients were followed for a mean of 24 years.

          Using standard-frame stereotactic techniques, custom DBS leads were implanted bilaterally in all patients in the ventral anterior limb or the internal capsule and adjacent ventral striatum (VC/VS). The initial site of VC/VS was based on anterior capsulotomy and later moved to a more posterior location. A second procedure under general anesthesia was performed to implant programmable pulse generators, which were subsequently programmed in an outpatient setting by psychiatrists.

          The primary outcome in this study was continuous measurements of the YBOCS score over time. A response to DBS (decline in the severity of OCD) over time was characterised as a full response for those who had at least a 35% YBOCS decrease from preimplantation baseline; a partial response for those who had at least a 25% YBOCS decrease but less than 35% reduction; and no response for those who had less then 25% YBOCS decrease.

          At 36 months after DBS, the study found a significant decrease in the mean YBOCS score for the 24 patients who reached a YBOCS score of 20.9 +-2.4 (P = .002). Patients considered full responders (>35% YBOCS decrease) increased from 28% at 1 month following DBS to 61.5% (16/26) at last follow-up. Patients who did not respond (<25% YBOCS decrease) declined from 68% (17/25) at 1 month to 27% at last follow-up.

          According to Dr. Rezai, these results show progressive improvement in YBOCS scores over time, even in the nonresponders group, which showed some improvement.

          The study also found that patients treated later in the series, when modifications to technique were used, had even better response scores: 33.3% were full responders in the first series of patients treated and 75% in the last series of patients treated.

          Overall, the treatment was well tolerated, with most adverse effects being only temporary.

          The authors concluded that DBS, conducted in the setting of a multidisciplinary team, is safe and effective for severely disabled patients with OCD refractory to previous treatments.

          Subjects were excluded from this study if they had a current or past history of a psychotic disorder, had substance-abuse problems, were at imminent risk of suicide, had a current clinically significant neurological disorder or medical illness, or had had a manic episode within the 3 years preceding the study.

          To date, DBS is used primarily as an adjuvant to ongoing medical and behavioural therapies that patients remain on after implantation. Although most patients can taper their medication dose, said Dr. Rezai, most stay on medication.

          Of the 2% to 3% of patients in the United States diagnosed with OCD, at least 10% remain refractory to treatment and remain markedly impaired in their ability to complete everyday activities. "These are patients who are very severely disabled from OCD for many years and can be described as in end-stage disease," noted Dr. Rezai.


          [Presentation title: Deep Brain Stimulation of the Ventral Internal Capsule/Ventral Striatum for Obessive-Compulsive Disorder: World-Wide Experience. Abstract 621]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send